Compare moats
Up to three covered companies, band by band. Every call is a curated editorial judgment, never a disclosed figure — and every band carries its cited basis.
| Penguin Solutions | TSMC | Pfizer | |
|---|---|---|---|
| Moat rating | none The FY2025 10-K (fiscal year ended August 29, 2025) documents design-in niches but no durable excess return. In favour: the Competition section says some large rivals 'tend to have limited customization and service capabilities and are generally focused on higher-volume memory, storage, or compute products that are manufactured to industry-standard specifications'. It says the company's 'close collaboration with customers, customer-specific designs, long-lifecycle solutions, superior products and proprietary supply chain services create significant customer loyalty that may provide an advantage when competing against large international companies'. Against: the same filing says many competitors have 'substantially greater financial, technical, marketing, distribution and other resources' and 'lower cost structures'. Sales are made 'primarily pursuant to customer purchase orders and are not based on long-term supply agreements', and 'customers are not obligated to purchase our products even if we achieve a design win'. Large customers 'have exerted' pressure for price concessions, and the ten largest were 66% of fiscal 2025 net sales. GAAP operating income was 0.6%, 1.6% and 4.2% of net sales in fiscal 2023, 2024 and 2025, and fiscal 2024 had a net loss from continuing operations of $41.8 million. The 10-Q for the quarter ended May 29, 2026 (filed 2026-07-07, https://www.sec.gov/Archives/edgar/data/1616533/000161653326000043/peng-20260529.htm) adds that Advanced Computing nine-month sales fell 20.6%, reflecting 'both the ongoing Penguin Edge wind down and hyperscale hardware sales in 2025 that did not recur in 2026'. The filing's own advantage claim is hedged ('may provide an advantage'): design-in niches exist, but the 10-K shows no durable excess return. | wide TSMC's 2025 Form 20-F reports a 59.9% gross margin (up from 56.1% in 2024) and describes the company as "the technology leader among the dedicated foundries" in advanced (7-nanometer-and-below) node revenue — a durable, hard-to-replicate process-and-scale advantage that rivals with "greater financial and other resources" have not matched. | eroding The FY2025 10-K publishes the expiry schedule of its own protection. The Patents table dates the basic U.S. product patent on Eliquis ($7,961 million of 2025 revenue) to 2027, the Prevnar family's Prevnar 13 ($6,494 million for the family) to 2026, the Vyndaqel family ($6,380 million) to 2026 with a 2028 extension only pending, Ibrance ($4,122 million) to 2027, Xtandi ($2,194 million) to 2027 and Xeljanz ($1,087 million) to 2026 - against Total revenues of $62,579 million. The filing then states it anticipates 'a significant reduction of revenue from patent-based or regulatory exclusivity expiries in 2026 through 2030 as several of our in-line products experience these expirations, with the rate of the reduction of revenues from patent-based or regulatory exclusivity expiries expected to significantly accelerate over the next few years', and puts the 2026 instalment at $1.5 billion. A protection whose end dates the issuer tabulates product by product, and whose revenue effect it forecasts as accelerating, is being consumed on a clock it has already disclosed. |
| Moat type | none The strongest candidate moat source in the 10-K is design-in and qualification, a switching-cost argument, and the filing limits it too far to count. The risk factors say 'Our products are often incorporated into customers' systems at the design stage', and many specialty products 'are specifically designed for our OEM customers' systems or products'. But qualification is 'both product-specific and platform-specific', so a design win covers one platform. The filing notes that customers 'sometimes require us to re-qualify our products' for new platforms, which 'can be time-consuming and cause reductions in our net sales', so each new platform reopens the socket. It also says 'customers are not obligated to purchase our products even if we achieve a design win', and warns that OEMs designing in 'standardized or commodity components' could reduce demand for its 'higher priced specialized or customized solutions'. Scale is ruled out because the filing says many competitors have lower cost structures. Patents are ruled out as a durable source. The company holds about 1,650 of them and calls intellectual property 'an important aspect of our business', but it says its patents 'do not cover all of our technologies' and that competitors 'may design around our patented technologies'. It also says some products are 'built around mature industry standards and have less patent protection', so 'we cannot prevent our competitors from reverse-engineering and duplicating those products'. | intangibles ip Per its 2025 Form 20-F, TSMC "compete[s] primarily on process technologies, manufacturing excellence, customer trust and service quality" and has "been issued a substantial number of patents," with 2-nanometer in volume production in 2025 and 16-angstrom risk production targeted for 2026 — proprietary process-technology know-how and IP, not merely capital (the filing explicitly notes some competitors may have greater financial resources yet still trail), are the core barrier. | intangibles ip The filing locates the protection in the patent estate, not anywhere else. The Patents and Other Intellectual Property Rights section tabulates 'the patent rights we consider most significant in relation to our business as a whole, together with the year in which the basic product patent expires', and states that once protection is lost 'we typically lose market exclusivity on these products, and generic and biosimilar pharmaceutical manufacturers generally produce identical or highly similar products and sell them for a lower price.' The Competition section names patents as the thing rivals attack: 'several of our competitors operate without large R&D expenses and make a regular practice of challenging our product patents before their expiration', and 'Generic pharmaceutical manufacturers pose one of the biggest competitive challenges to our branded small molecule products because they can market a competing version of our product after the expiration or loss of our patent protection.' No network, switching cost or cost-curve advantage is claimed anywhere in the section. |
| Leadership | at parity The 10-K claims no share figure or rank in any segment. It says 'Our businesses compete with numerous global and local companies'. Its HPC and AI business 'competes primarily with global manufacturers of HPC and AI products and services'. For fault-tolerant solutions it says 'we primarily compete with manufacturers of enterprise servers and industrial computers'. Its memory business competes 'against memory module providers and, to a lesser extent, large semiconductor manufacturers'. The risk factors warn that larger competitors 'may be able to respond better to new or emerging technologies, such as generative AI'. Against that, the company's stated edge is customization and service, where it says some large rivals 'tend to have limited customization and service capabilities'. Its leadership language is self-description without share figures: Cree LED 'has been a leader in LED lighting technology', Stratus Technologies is 'a global leader in simplified, protected and autonomous computing platforms and services', and the memory business is 'a primary supplier of longer-lifecycle solutions to OEM customers'. A specialist that claims no rank and faces many larger, lower-cost rivals, while neither leading nor clearly trailing in its niches, is parity. | clear leader Self-described in its 2025 20-F as "the technology leader among the dedicated foundries" in net revenue of advanced semiconductors at 7-nanometer and below; reached 2nm volume production in 2025, and Epoch AI estimates ~90% share of global advanced-node fabrication. | co leader The 2026 Pharma 50 (Drug Discovery & Development, published 31 March 2026, ranking pharmaceutical revenue only) places Pfizer third at $62.58 billion of FY2025 revenue inside a five-company band that runs from Johnson & Johnson's Innovative Medicine at $60.40 billion to Eli Lilly's $65.18 billion, with Merck & Co. at $65.01 billion and AbbVie at $61.16 billion in between - scale-equal to its nearest peers rather than ahead of them. The same piece attributes the top slot to Lilly's tirzepatide franchise, which it puts at $36.5 billion combined and says passed Keytruda as the world's best-selling drug; Pfizer's 10-K names no comparable single franchise, discloses no market-share position for any product, and concedes in Item 1A that 'some of our competitors may have competitive, technical or other advantages over us' and that it faces 'an increasing number of potential competitors worldwide, including from China, that have expanded R&D capabilities.' |
| Pricing power | weak The FY2025 10-K describes price as set by customers and the market. It says its large customers 'are able to exert, have exerted and we expect will continue to exert, pressure on us to make concessions on price and on terms and conditions'. It says 'The markets for our Integrated Memory products have historically been characterized by declines in average selling prices', and that 'Competitive pressure has led in the past and may continue to lead to intensified price competition resulting in lower net sales and lower profit margins'. Gross margin held in a narrow band: 28.8% in fiscal 2023, 29.1% in fiscal 2024 and 28.8% in fiscal 2025. The filing attributes each move to mix, for example higher-margin Advanced Computing service revenue in 2024, not to pricing. The 10-Q for the quarter ended May 29, 2026 (filed 2026-07-07, https://www.sec.gov/Archives/edgar/data/1616533/000161653326000043/peng-20260529.htm) reports gross margin of 27.8% versus 29.3% a year earlier (27.7% versus 28.9% for nine months), which it attributes to the Penguin Edge wind-down and sales mix. Third-quarter Integrated Memory sales rose 111.4% (75.6% for nine months) as 'accelerating AI-driven demand drove favorable pricing and increased volume', and the 10-Q says that business has 'gross margins which are lower than the Company average'. | strong 2025 gross margin of 59.9% (up from 56.1% in 2024), attributed in the 20-F to higher capacity utilization and cost improvement, reflects strong pricing power at the leading edge despite the heavy capital intensity of new-node ramps. | weak Price is the lever the filing shows moving against it. CMS selected Eliquis - which the 10-K says 'accounted for 13% of Total revenues in 2025' - for the Medicare Drug Price Negotiation Program, and 'its government-set Maximum Fair Price became effective January 1, 2026', with Ibrance and Xtandi following in 2027 and Xeljanz in 2028. In September 2025 Pfizer 'voluntarily agreed' with the U.S. administration to make certain U.S. prices 'more comparable to those in other developed countries' and to sell through the TrumpRx.gov platform 'at significant discounts to current retail prices'. Gross-to-net product revenue deductions rose to $36,374 million in 2025 from $30,048 million in 2023 while Total revenues fell to $62,579 million, and the IRA Medicare Part D Redesign alone 'negatively impacted our 2025 revenues by approximately $1 billion'. Lower U.S. net price is named as a drag on Vyndaqel, Ibrance, Xeljanz, Nurtec ODT and Lorbrena; every 2025 growth line the filing explains is attributed to demand, patient share or launch uptake, none to price. Cost of sales at 25.7% of revenues shows the manufactured margin is intact - what is not intact is the ability to set the price. |
| Summary | Penguin Solutions (formerly SMART Global Holdings) has three reportable segments per the FY2025 10-K. Advanced Computing ($648.4 million of fiscal 2025 net sales) designs, builds, deploys and manages AI and HPC clusters under OriginAI with the ICE ClusterWare software, and sells Stratus fault-tolerant servers. Integrated Memory ($464.2 million) sells SMART Modular specialty DRAM, flash and CXL memory and supply-chain services. Optimized LED ($256.1 million) sells Cree LED chips and components. Its advantage is customization rather than size. The filing says its memory business collaborates with OEMs 'throughout their design process across multiple projects' and is 'a primary supplier of longer-lifecycle solutions to OEM customers' in industrial, government, networking and enterprise markets. Its products must pass product- and platform-specific qualification, and some large rivals focus on higher-volume, industry-standard products. The limits are just as clear. Many competitors are larger and have lower cost structures. Customers buy on purchase orders, the ten largest were 66% of fiscal 2025 sales, and they 'have exerted' pressure for price concessions. Integrated Memory has historically seen declining average selling prices. AI hardware revenue is project-driven: Advanced Computing sales fell 26.0% in fiscal 2024 on 'the unpredictable nature of large project engagements'. The 10-Q for the quarter ended May 29, 2026 (filed 2026-07-07, https://www.sec.gov/Archives/edgar/data/1616533/000161653326000043/peng-20260529.htm) says the AI infrastructure business is 'transitioning from a hyperscaler concentration toward a more diversified non-hyperscaler customer base across enterprise, neocloud, and sovereign AI', which 'may negatively impact our net sales during the transition'. The result is a set of design-in niches rather than a franchise, with an AI business that must keep re-winning large deployments. | TSMC is the world's largest dedicated semiconductor foundry and, per its 2025 Form 20-F, the self-described technology leader among dedicated foundries in advanced (7nm-and-below) node revenue, having reached 2-nanometer volume production in 2025 with 16-angstrom risk production on track for 2026. Independent research (Epoch AI) estimates it controls roughly 90% of global advanced-node fabrication; sustained by US$7.9 billion of 2025 R&D, a large patent portfolio and 59.9% gross margins, this process-technology and scale advantage has proven durable even against rivals with greater financial resources. | Two clocks run in opposite directions inside the same company. The revenue base is near-dated: Eliquis, the Prevnar family, the Vyndaqel family, Ibrance, Xtandi and Xeljanz all carry U.S. basic product patents expiring 2026 or 2027 in the 10-K's own table, and the filing warns the resulting revenue loss will 'significantly accelerate over the next few years'. The replacement book is later-dated - Padcev and Lorbrena to 2033, Nurtec ODT and Litfulo to 2034, Prevnar 20 to 2035, Abrysvo, Cibinqo and Elrexfio to 2036, Comirnaty and Paxlovid to 2041 - but in 2025 it was still much smaller, and the two products with the longest patent runway are the two the filing says are shrinking fastest (Comirnaty down 20% and Paxlovid down 59% operationally). The 10-K's answer is purchased pipeline rather than defended position: it cites the Seagen and Metsera acquisitions as 'significant investments in obesity and oncology, respectively, which are extremely competitive therapeutic areas', while R&D expense itself fell 4% to $10,437 million. Excluding Comirnaty and Paxlovid the remaining business grew 6% operationally in 2025, which is the honest measure of what is being rebuilt underneath the expiries. A third pressure sits on top of the patent clock and is independent of it: government price-setting now reaches the largest product in the book. |
| Chain position | Downstream integrator. Per the 10-K it buys memory from Samsung, Micron, SK hynix and Kioxia and processors from Intel and AMD, and turns them into specialty memory modules and managed AI/HPC clusters for OEM, enterprise, government and cloud customers. | The critical leading-edge fabrication and advanced-packaging (CoWoS) layer of the AI supply chain — high-performance computing was 58% of TSMC's 2025 revenue, and it supplies leading-edge N2/N3/N4 logic to the fabless IC-design and system companies that design AI accelerators. | Demand side of the AI chain, not a supplier into it. The 10-K lists 'Scale AI across our business' as one of four 2026 key priorities and describes 'expanding automation, data-driven decision making, and enterprise AI solutions', crediting 'enhanced digital enablement, including automation and AI' for part of the savings in its cost-realignment and R&D-simplification programs. It describes no AI model, tool or platform that Pfizer sells. |
| Products (share / barrier) |
|
|
|
| Long-horizon vote | -0.06 at weight 0.20 · swarm neutral Editorial prior, not backtested. | +0.42 at weight 0.20 · swarm bullish Editorial prior, not backtested. | -0.17 at weight 0.20 · swarm bearish Editorial prior, not backtested. |